Pediatrix Medical vs Privia Health
MD and PRVA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MD and PRVA compare
Privia Health is the larger company, worth 1.2 times as much as Pediatrix Medical ($3.1B against $2.5B).
On earnings, Pediatrix Medical is cheaper: it trades at 17.1× trailing earnings, against 92.5× for Privia Health.
Privia Health grew revenue faster over the last twelve months (19.2% versus 1.9% for Pediatrix Medical).
Pediatrix Medical keeps more of each dollar of sales as profit, with a net margin of 7.7% compared with 1.4% at Privia Health.
Privia Health scores higher on the StockData Score (15 against 10 for Pediatrix Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MD | PRVA |
|---|---|---|
| Size and price | ||
| Market cap | $2.5B | $3.1B |
| Share price | $31.45 | $24.04 |
| Change, 1 year | 39.3% | 2.7% |
| Change, 5 years | 21.8% | −16.7% |
| Beta (5Y) | 0.68 | 0.65 |
| Employees | – | 1,226 |
| StockData Score | ||
| Total score | 10 | 15 (better) |
| Valuation score | 2 | 2 |
| Growth score | 1 | 3 (better) |
| Performance score | 4 | 4 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.1× (better) | 92.5× |
| P/S | 1.3× (better) | 1.3× |
| P/B | 2.9× (better) | 3.8× |
| EV/EBITDA | 11.0× (better) | 42.0× |
| PEG | 0.49 | – |
| Fair value | $29.34 | $15.41 |
| Margin of safety | −7.2% (better) | −56.0% |
| Growth | ||
| Revenue growth (TTM) | 1.9% | 19.2% (better) |
| Revenue growth, 5Y average | 2.0% | 21.0% (better) |
| Net income growth (TTM) | −7.5% | 91.3% (better) |
| EPS growth (TTM) | −3.2% | 100% (better) |
| EPS growth, 5Y average | – | −11.4% |
| Profitability | ||
| Operating margin | 10.9% (better) | 2.1% |
| Net margin | 7.7% (better) | 1.4% |
| Return on equity | 17.2% (better) | 4.6% |
| Return on invested capital | 15.4% (better) | 10.0% |
| Financial health | ||
| Debt / equity | 0.68 (better) | 0.00 |
| Net debt / EBITDA | 0.64 | – |
| Interest coverage | 6.4× | – |
| Current ratio | 1.28 | 1.63 (better) |
| Altman Z-score | 2.47 | 4.54 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Buyback yield | 8.5% | – |
| Shareholder yield | 8.5% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 107% | 96.7% |
| Held by insiders | 1.5% | 7.1% |
| Insider net buying, 12 months | −$1.4M (better) | −$22.2M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 4.6% | 3.3% |
Go deeper
- MD stock overview
- MD income statement
- MD valuation and score
- PRVA stock overview
- PRVA income statement
- PRVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.